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Background
Unilateral ureteral obstruction (UUO) is characterized by
progressive renal atrophy, tubular apoptosis and tubu-
lointerstitial fibrosis. Pharmacological stimulation of sol-
uble guanylate cyclase (sGC) and subsequent cGMP
production have recently been found to be renoprotec-
tive. In this study, the sGC stimulator BAY 41-8543 was
given to rats after relief of UUO in order to analyze the
effects of enhanced NO/sGC/cGMP signaling on the sub-
sequent renal disease recovery, concerning the renal atro-
phy, tubular apoptosis and tubulointerstitial fibrosis.
Methods
Male Sprague-Dawley rats underwent UUO. After 5 days,
the obstruction was relieved and the rats were randomly
assigned to UUO-Relief and UUO-Relief plus BAY 41-
8543 (10 mg/kg body weight/day). After 7 days of treat-
ment, effects of stimulated sGC/cGMP on plasma cGMP
levels, systolic blood pressure and renal histology were
determined. The symbol * indicates p < 0.05 UUO-Relief
versus UUO-Relief plus BAY 41-8543.
Results
Untreated UUO-Relief rats showed elevation of systolic
blood pressure, marked tubular atrophy, tubular apopto-
sis, tubulointerstitial macrophage infiltration and fibrosis.
Compared to the untreated rats with UUO-Relief, BAY 41-
8543 treatment increased significantly plasma cGMP lev-
els (+104%*). This went along with significant reductions
in systolic blood pressure (UUO-Relief plus BAY 41-8543
vs UUO-Relief: 112 ± 4 vs 145 ± 8 mmHg*), tubular
diameter (-20%*), tubular apoptosis (-67%*) shown in
TUNEL assay, tubulointerstitial macrophage infiltration (-
65%*) and fibrosis (tubulointerstitial volume -38%*,
expansion of matrix proteins -60%*, deposition of colla-
gen IV -52%* and expression of alpha-smooth muscle
actin -69%*).
Conclusion
Stimulation of sGC by Bay 41-8543 significantly increased
cGMP production and precedes the disease resolution fol-
lowing relief of UUO. This involved improvements in
renal atrophy, tubular apoptosis, tubulointerstitial fibro-
sis and macrophage infiltration. The findings suggest that
pharmacological sGC stimulation is an effective approach
to accelerate restoration of renal architecture and function
following relief of ureteral obstruction.
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